Invanz

Ertapenem Sodium

6.4 Moderate risk

Invanz & Product use in unapproved indication

18.6%

of users reported Product use in unapproved indication

83.3%

also reported Severe reaction

52.4%

are women

Most common medical consequences

Severe reaction
83.3%
Hospitalization
8.3%
Disability
8.3%

Have you experienced any negative side effects from this medication?

Invanz: general information

Most common side effects (32)

Most commonly affected ages

0 - 9 years
1.4%
10 - 19 years
<0.1%
20 - 29 years
2.7%
30 - 39 years
1.4%
40 - 49 years
3.1%
50 - 59 years
12.3%
60 - 69 years
23.0%
70 - 79 years
26.0%
80 - 89 years
24.6%
90 - 99 years
5.4%
On this page
Invanz & Product use in unapproved indication
Invanz: general information